- First Online:
- Cite this article as:
- Lyseng-Williamson, K.A. & Keating, G.M. Am J Clin Dermatol (2013) 14: 61. doi:10.1007/s40257-012-0004-6
- 323 Views
Vismodegib is the first Hedgehog pathway inhibitor to be approved in the USA, where it is indicated for the treatment of adults with metastatic basal cell carcinoma (BCC), or with locally advanced BCC that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation. In an ongoing, noncomparative, phase II trial, oral vismodegib was effective in and had an acceptable tolerability profile in the treatment of patients with locally advanced or metastatic BCC.